Kaftrio (Elexacaftor/Tezacaftor/Ivacaftor)

Kaftrio (elexacaftor/tezacaftor/ivacaftor), from Vertex Pharmaceuticals, is the EU brand name for the triple-combination CFTR modulator therapy (marketed as Trikafta in the US) indicated for the treatment of cystic fibrosis (CF) in patients with at least one F508del mutation in the CFTR gene, or other responsive mutations, as determined by an approved genotype.

Kaftrio combines three CFTR modulators: elexacaftor and tezacaftor help the defective CFTR protein fold and traffic correctly to the cell surface, while ivacaftor acts as a potentiator, keeping the CFTR channel open longer to improve chloride transport. Together they improve the function of the underlying defective protein responsible for cystic fibrosis.

• Liver function abnormalities can occur; liver function tests are recommended before starting and periodically during treatment.
• Cataracts (non-congenital lens opacities) have been reported in pediatric patients; eye examinations are recommended.
• Drug interactions are common, particularly with strong CYP3A inhibitors/inducers — a full medication history should be reviewed before starting.
• Common side effects: headache, diarrhea, elevated liver enzymes, rash, upper respiratory tract infection.

What documents are required to import Kaftrio to India?

Kaftrio may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered pulmonologist specifying Kaftrio and dose
• CFTR genetic test report confirming an eligible mutation
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is Kaftrio available in India?

Kaftrio is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source Kaftrio from Vertex Pharmaceuticals’ authorized European distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For Kaftrio cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• European Union: Approved by the EMA (marketed as Kaftrio).
• United States: Same combination approved by the FDA as Trikafta.

What is Kaftrio used for?

Kaftrio treats cystic fibrosis in patients with at least one F508del CFTR mutation or other responsive mutations.

Who manufactures Kaftrio?

Kaftrio is manufactured by Vertex Pharmaceuticals.

Is Kaftrio the same as Trikafta?

Yes — Kaftrio is the EU brand name for the same elexacaftor/tezacaftor/ivacaftor combination marketed as Trikafta in the United States.

How much does Kaftrio cost in India?

Cost depends on monthly quantity and sourcing logistics — share your prescription and genetic test report with IPN for a quote.